home / stock / bicx / bicx news

BICX News and Press, BioCorRx Inc. From 08/16/21

Stock Information
Company Name: BioCorRx Inc.
Stock Symbol: BICX
Market: OTC
Website: biocorrx.com
Menu
BICX BICX Quote BICX Short BICX News BICX Articles BICX Message Board
Get BICX Alerts

News, Short Squeeze, Breakout and More Instantly...
BICX - BioCorRx Provides Business Update for the Second Quarter of 2021

ANAHEIM, CA, Aug. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the second quarter ende...
BICX - BioCorRx Welcomes Four Experts to Expanded Scientific Advisory Board

ANAHEIM, CA, June 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc . (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today announced the addition...

BICX - BioCorRx posts wider Q1 loss, raises going concern doubts

BioCorRx ([[BICX]]) posted a wider first-quarter net loss and said that it had "substantial doubt" about being able to continue as a going concern.The company believes that its current cash on hand will not be sufficient to fund its projected operating requirements for the next twelve mo...

BICX - BioCorRx reports Q1 results

BioCorRx (BICX): Q1 GAAP EPS of -$0.26.Revenue of $0.01M (-75.0% Y/Y)Shares +3.96% PM.10QPress Release For further details see: BioCorRx reports Q1 results

BICX - BioCorRx Provides Business Update for the First Quarter of 2021

ANAHEIM, CA, May 18, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc . (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business...

BICX - BioCorRx gets FDA clearance for BICX104 Opioid Use Disorder treatment trials

BioCorRx (BICX) announces that the U.S. FDA has given the company clearance to proceed to human trials for BICX104, an implantable naltrexone pellet for the treatment of Opioid Use Disorder ((OUD)).BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone being developed ...

BICX - BioCorRx Receives FDA Clearance of Investigational New Drug (IND) Application for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder

ANAHEIM, CA, May 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc . (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that the ...
BICX - BioCorRx submits Opioid Use Disorder treatment BICX104's IND to the FDA

BioCorRx (BICX) announces that the company has filed an Investigational New Drug ((IND)) application with the U.S. FDA for initiation of a clinical trial of BICX104, a naltrexone pellet implant for the treatment of Opioid Use Disorder ((OUD)).BICX104 is a biodegradable, long-acting subcu...

BICX - BioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone

ANAHEIM, CA, April 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc . (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that the Co...

BICX - BioCorRx Provides 2020 Year-End Business Update

ANAHEIM, CA, April 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a year-end business update for 2020 and repor...
Previous 10 Next 10